PMID- 29316164
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 6
DP  - 2018 Jun
TI  - Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or 
      dapagliflozin, added to metformin monotherapy, on body weight, systolic blood 
      pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 
      study.
PG  - 1515-1519
LID - 10.1111/dom.13206 [doi]
AB  - This post hoc analysis assessed the effects on cardiovascular risk factors of 
      body weight, systolic blood pressure (SBP) and triglycerides after 28 weeks' 
      treatment with exenatide once weekly plus dapagliflozin, as compared with 
      exenatide once weekly or dapagliflozin, in patient subpopulations from the 
      DURATION-8 trial of patients with type 2 diabetes mellitus (T2DM) inadequately 
      controlled with metformin alone. Subgroups of patients were stratified according 
      to their baseline body weight, SBP and triglyceride levels. Body weight, SBP and 
      triglyceride levels were reduced across most respective subgroups, with no 
      significant subgroup-by-treatment interactions. For each treatment, weight loss 
      was numerically greater as baseline body mass index increased. SBP reductions 
      were greater among patients with SBP >/=140 vs <140 mm Hg for exenatide once weekly 
      plus dapagliflozin and exenatide once weekly. Reductions in triglyceride levels 
      were greater among patients with baseline triglycerides <1.69 vs >/=1.69 mmol/L for 
      each treatment. The combination of exenatide once weekly plus dapagliflozin 
      reduced cardiovascular risk factors across baseline subgroups for each variable 
      to a greater extent than did either individual drug; the greatest effects were 
      observed in the high baseline subgroups for body weight and SBP.
CI  - (c) 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Jabbour, Serge A
AU  - Jabbour SA
AUID- ORCID: 0000-0002-4080-0470
AD  - Division of Endocrinology, Diabetes & Metabolic Diseases, Sidney Kimmel Medical 
      College of Thomas Jefferson University, Philadelphia, Pennsylvania.
FAU - Frias, Juan P
AU  - Frias JP
AUID- ORCID: 0000-0001-9486-1255
AD  - National Research Institute, Los Angeles, California.
FAU - Guja, Cristian
AU  - Guja C
AUID- ORCID: 0000-0002-8703-0522
AD  - Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University 
      of Medicine and Pharmacy, Bucharest, Romania.
FAU - Hardy, Elise
AU  - Hardy E
AD  - AstraZeneca, Gaithersburg, Maryland.
FAU - Ahmed, Azazuddin
AU  - Ahmed A
AD  - Apex Medical Research, Chicago, Illinois.
FAU - Ohman, Peter
AU  - Ohman P
AD  - AstraZeneca, Gaithersburg, Maryland.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20180204
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Triglycerides)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 9100L32L2N (Metformin)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Anti-Obesity Agents/administration & dosage
MH  - Benzhydryl Compounds/*administration & dosage
MH  - Blood Pressure/drug effects
MH  - Body Mass Index
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Exenatide/*administration & dosage
MH  - Glucosides/*administration & dosage
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Metformin/*administration & dosage
MH  - Sodium-Glucose Transporter 2 Inhibitors/administration & dosage
MH  - Triglycerides/metabolism
PMC - PMC5969082
OTO - NOTNLM
OT  - GLP-1 analogue
OT  - SGLT2 inhibitor
OT  - dapagliflozin
OT  - exenatide
OT  - type 2 diabetes
COIS- S.A.J. has worked as a consultant for AstraZeneca, Eli Lilly, and Janssen. J.P.F. 
      has received research support from AbbVie, AstraZeneca, Boehringer Ingelheim, 
      Bristol-Myers Squibb, Eli Lilly, IONIS, Janssen, Johnson and Johnson, Ligand, 
      Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Theracos, and vTv 
      Therapeutics, and has participated in scientific advisory boards and received 
      consulting fees from AstraZeneca, Bristol-Myers Squibb, Novo Nordisk, Sanofi, and 
      Theracos. C.G. has participated in scientific advisory boards and received 
      consulting fees from Alfa Wasserman, AstraZeneca, Bayer AG, Berlin-Chemie 
      Menarini, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi. A.A. has 
      received research grants from AbbVie, AstraZeneca, Kowa Pharmaceuticals, Novo 
      Nordisk, and Sanofi-Aventis. E.H. and P.O. are employees of AstraZeneca.
EDAT- 2018/01/10 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/05/25
CRDT- 2018/01/10 06:00
PHST- 2017/10/17 00:00 [received]
PHST- 2017/12/26 00:00 [revised]
PHST- 2017/12/29 00:00 [accepted]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/05/25 00:00 [pmc-release]
AID - DOM13206 [pii]
AID - 10.1111/dom.13206 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 Jun;20(6):1515-1519. doi: 10.1111/dom.13206. Epub 2018 
      Feb 4.